Heparastatin is a heparanase inhibitor.
Addition of 100 μM of Heparastatin (SF4) completely inhibits the enzyme activity of heparanase at a concentration of 0.15 μg/mL in an in vitro degradation assay. Addition of Heparastatin during the transition process does not affect the phenotypic change of TGF-β-treated cells[2].
[1]. Sue M, et al. An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into inflamed dorsal air pouches. Int Immunopharmacol. 2016 Jun;35:15-21. [2]. Yusuke Kogane, et al. Heparanase Downmodulation in the Process of Epithelial-to-Mesenchymal Transition of Mouse Mammary Epithelial Cells. Kogane et al., J Glycomics Lipidomics 2013, 3:1.